Last updated: February 14, 2026
What Is the Drug Identified by NDC 00008-0836?
The NDC 00008-0836 corresponds to Dextroamphetamine-Amphetamine (Adderall), a central nervous system stimulant used primarily for treatment of ADHD and narcolepsy. It is a brand-name drug produced by Teva Pharmaceuticals. The product is available in various dosages and formulations.
Market Size and Trends
Global and U.S. Market Scope
- The U.S. leads the worldwide market for ADHD medications, with current sales estimated at approximately $10 billion annually.
- The ADHD drug market has experienced compounded growth at a CAGR of approximately 6-8% over the past five years.
Market Drivers
- Rising ADHD diagnosis rates, now affecting about 9.4% of children in the U.S. (CDC, 2022).
- Growing awareness and acceptance of medication treatment.
- Expanded prescribing for adults aged 18-44, accounting for nearly 50% of prescriptions in 2022.
Competitive Landscape
- Leading brands include Adderall (teva) and generics.
- Major generic competitors: Mylan, Sandoz, and other pharmaceutical companies.
- Patent expiration for the brand Adderall in the U.S. occurred in 2023, increasing generic market share.
Pricing Analysis
Current Pricing Landscape
- The average wholesale price (AWP) for Adderall 30 mg immediate-release tablets: approximately $0.60 per tablet.
- Generic versions price around $0.25–$0.50 per tablet, reflecting significant price erosion post-patent expiry.
- Contract drug acquisition costs for pharmacies are typically 30-50% lower than the AWP.
Pricing Trends
- Post-patent expiration, prices drop 20-50% due to increased generic competition.
- Retail pharmacy prices for 30-count prescriptions: $10–$15 for generics.
- Patients with insurance pay mainly copays, typically in the $10–$50 range.
Forecasted Price Trajectory
| Year |
Estimated Wholesale Price (per 30 mg tablet) |
Notes |
| 2023 |
$0.25–$0.60 |
Patent expired; generic entry increasing |
| 2024 |
$0.20–$0.55 |
Market stabilization; volume rise |
| 2025 |
$0.15–$0.50 |
Further competition; price erosion |
Forecasts suggest prices will stabilize or decline slightly in the near term as generics dominate. Retail and wholesale prices could dip 15-30% from current levels over the next two years.
Market Opportunities and Risks
Opportunities
- Expansion into new formulations (e.g., extended-release, transdermal patches)
- Increased adult ADHD prescriptions.
- Penetration into emerging markets with rising ADHD diagnosis.
Risks
- Regulatory challenges surrounding abuse potential and scheduling.
- Pricing pressure from generic manufacturers.
- Government pricing policies aimed at reducing costs for public drug programs.
Regulatory and Policy Environment
- The Drug Enforcement Administration (DEA) classifies amphetamines as Schedule II controlled substances, affecting prescribing, manufacturing, and distribution.
- Price controls or adjustments under Medicaid and Medicare Part D could influence reimbursement levels.
Key Takeaways
- The drug's primary market, the U.S., exceeds $10 billion annually for ADHD treatments.
- Post-patent expiration, prices for NDC 00008-0836 have decreased significantly, with continued downward pressure forecasted.
- Opportunities exist in expanding forms and markets but face challenges from regulatory and pricing pressures.
FAQs
1. What factors influence the price of NDC 00008-0836?
Market competition, patent status, regulatory changes, and prescribing trends influence pricing. Generics tend to lower prices post-patent expiration.
2. How does the U.S. market compare with international markets?
The U.S. dominates global sales, driven by diagnosis rates and healthcare infrastructure. International markets are growing but remain smaller.
3. What is the impact of patent expiration on pricing?
Patent expiry introduces generic competition, reducing prices by up to 50%, and increasing market volume.
4. What are projected future prices for this drug?
Prices are expected to stabilize or decline marginally, with an approximate 15-30% decrease over two years, depending on market dynamics.
5. Are there regulatory risks impacting pricing?
Yes. Policies targeting controlled substances and reimbursement adjustments can influence both supply and prices.
Citations
[1] Centers for Disease Control and Prevention (CDC). "Data & Statistics on ADHD." 2022.
[2] IQVIA. "Pharmaceutical Market Analysis," 2022.
[3] FDA. "ANDA Approvals and Patent Status for Adderall," 2023.
[4] Bloomberg Intelligence. "Global ADHD Drug Market Insights," 2022.
